Image

Global Liver Fibrosis Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Liver Fibrosis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Liver Fibrosis Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 16.45 USD Billion
Diagram Market Size (Forecast Year) USD 38.74 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Liver Fibrosis Market, By Condition (Chronic Liver Diseases, Hepatitis C, Nonalcoholic Steatohepatitis), Treatment (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Nonsurgical Tests, Transient Elastography, Liver Biopsy, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Liver Fibrosis Market

Market Analysis and Size

In recent years, the liver fibrosis market is anticipated to grow rapidly during the forecast period. As per the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities worldwide, with 1 million deaths due to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Healthcare practitioners concentrate on treating liver fibrosis by addressing the underlying cause of the disease to prevent or slow the scarring of the liver. Chronic alcohol consumption, autoimmune hepatitis, storage and metabolism disorders such as Wilson disease, Galactosemia, Fructosemia, glycogen storage diseases, iron overload symptoms, Gaucher disease, bacterial, parasite, and viral infections, and disorders affecting hepatic blood flow, among others, are all possible risk factors for liver fibrosis management.

Data Bridge Market Research analyses that the liver fibrosis market was valued at USD 16.45 billion in 2021 and is expected to reach USD 38.74 billion by 2029, registering a CAGR of 11.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Repeated or persistent liver damage results in an unusually high quantity of scar tissue in the liver, which is known as liver fibrosis. Fibrosis has no symptoms, but extensive scarring causes cirrhosis, which causes symptoms. Healthcare providers use blood and imaging tests to determine the severity of the condition, and liver biopsy. Healthcare practitioners focus on treating the source of liver fibrosis, which often stops or slows additional scarring of the liver and leads to a better outcome. Antiviral medications and the removal or dissolution of a blockage in the bile ducts, are all potential treatments for liver fibrosis.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Condition (Chronic Liver Diseases, Hepatitis C, Nonalcoholic Steatohepatitis), Treatment (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Nonsurgical Tests, Transient Elastography, Liver Biopsy, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Vertex Pharmaceuticals Incorporated (US), FibroGen, Inc. (US), Pharmaxis Ltd (Australia), Dicerna Pharmaceuticals, Inc. (US), Dynavax Technologies (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Liver Fibrosis Market Dynamics

Drivers

  • Increasing prevalence of liver fibrosis

The rising prevalence of liver fibrosis across the globe is estimated to enhance the market's growth. Along with this, the surging prevalence of risk factors such as chronic hepatitis B or C infection, a weakened immune system due to HIV co-infection, or the use of immunosuppressive medicines after a liver transplant is projected to enhance the liver fibrosis market.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of liver fibrosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to liver fibrosis, further estimated to enhance the 'market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the liver fibrosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and rising disposable income will result in the expansion of liver fibrosis market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the liver fibrosis market growth. Along with this, rising drug approvals and launches will further propel the 'market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the liver fibrosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the liver fibrosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This liver fibrosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liver fibrosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Liver fibrosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Liver Fibrosis Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the liver fibrosis market.

Recent Development

  • In January 2022, Siemens Healthineers announced the launch of the Enhanced Liver Fibrosis (ELF) Test in the U.S. this test offers broad clinical access to the minimally invasive prognostic tool. The ELF Test is a simple, efficient blood test for determining prognosis in individuals with advanced fibrosis (F3 or F4) caused by non-alcoholic steatohepatitis (NASH), a kind of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation.

Global Liver Fibrosis Market Scope

The liver fibrosis market is segmented on the basis of condition, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Condition

Route of Administration

  • Oral
  • Parenteral
  • Others

Diagnosis

  • Nonsurgical Tests
  • Transient Elastography
  • Liver Biopsy
  • Others

Treatment

  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
  • ACE Inhibitors
  • Hepatotropic Drug
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Liver Fibrosis Market Regional Analysis/Insights

The liver fibrosis market is analysed and market size insights and trends are provided by country, condition, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the liver fibrosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the liver fibrosis market because of the presence of variety of innovative drug molecule to enhance the treatment procedure and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the 'market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing prevalence of liver disorders in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Liver Fibrosis Market Share Analysis

The liver fibrosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to liver fibrosis market.

Some of the major players operating in the liver fibrosis market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • AstraZeneca (UK)
  • Johnson & Johnson Private Limited (US)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Merck & Co., Inc. (US)
  • Bristol-Myers Squibb Company (US)
  • Gilead Sciences, Inc. (US)
  • Vertex Pharmaceuticals Incorporated (US)
  • FibroGen, Inc. (US)
  • Pharmaxis Ltd (Australia)
  • Dicerna Pharmaceuticals, Inc. (US)
  • Dynavax Technologies (US)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The market value for Liver Fibrosis Market is expected USD 38.74 billion by 2029.
The Liver Fibrosis Market is to grow at a CAGR of 11.30% during the forecast by 2029.
The major players operating in the Liver Fibrosis Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Vertex Pharmaceuticals Incorporated (US), FibroGen, Inc. (US), Pharmaxis Ltd (Australia), Dicerna Pharmaceuticals, Inc. (US), Dynavax Technologies (US).
The major countries covered in the Liver Fibrosis Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials